BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND CgA AND Staging
24 results:

  • 1. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
    Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
    [No Abstract]    [Full Text] [Related]  

  • 2. Plasma Progastrin-Releasing Peptide and Chromogranin A Assays for Diagnosing and Monitoring Lung Well-Differentiated Neuroendocrine tumors: A Brief Report.
    Nisman B; Oleinikov K; Nechushtan H; Maimon O; Atlan K; Peled N; Gross D; Peretz T; Meirovitz A; Grozinsky-Glasberg S
    J Thorac Oncol; 2023 Mar; 18(3):369-376. PubMed ID: 36503175
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.
    Wu Y; Lai Y; Zhang M; Li Z
    Diagn Pathol; 2021 Aug; 16(1):78. PubMed ID: 34454530
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation.
    Noor M; Huber AR; Cates JMM; Gonzalez RS
    Histopathology; 2021 Sep; 79(3):416-426. PubMed ID: 33754384
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine tumors: An ENETS Center of Excellence Experience.
    Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
    Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
    Ohlendorf F; Henkenberens C; Brunkhorst T; Ross TL; Christiansen H; Bengel FM; Derlin T
    Q J Nucl Med Mol Imaging; 2022 Dec; 66(4):361-371. PubMed ID: 32286768
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
    Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
    Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
    Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
    Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
    Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
    Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
    Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Surgical Management of Small Bowel Neuroendocrine tumors: Specific Requirements and Their Impact on staging and Prognosis.
    Pasquer A; Walter T; Hervieu V; Forestier J; Scoazec JY; Lombard-Bohas C; Poncet G
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S742-9. PubMed ID: 26014153
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.
    Bodei L; Kidd M; Modlin IM; Prasad V; Severi S; Ambrosini V; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G; Drozdov I
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1341-52. PubMed ID: 25947577
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Neuroendocrine tumors of the bronchopulmonary system (typical and atypical carcinoid tumors): current strategies in diagnosis and treatment. Conclusions of an expert meeting February 2011 in Weimar, germany.
    Hörsch D; Schmid KW; Anlauf M; Darwiche K; Denecke T; Baum RP; Spitzweg C; Grohé C; Presselt N; Stremmel C; Heigener DF; Serke M; Kegel T; Pavel M; Waller CF; Deppermann KM; Arnold R; Huber RM; Weber MM; Hoffmann H
    Oncol Res Treat; 2014; 37(5):266-76. PubMed ID: 24853787
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Evaluation of radiological prognostic factors of hepatic metastases in patients with non-functional pancreatic neuroendocrine tumors.
    Denecke T; Baur AD; Ihm C; Steffen IG; Tischer E; Arsenic R; Pascher A; Wiedenmann B; Pavel M
    Eur J Radiol; 2013 Oct; 82(10):e550-5. PubMed ID: 23891296
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Selected neuroendocrine tumour markers, growth factors and their receptors in typical and atypical bronchopulmonary carcinoids.
    Telega A; Kos-Kudła B; Foltyn W; Blicharz-Dorniak J; Rosiek V
    Endokrynol Pol; 2012; 63(6):477-82. PubMed ID: 23339006
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Comparison of PCR-based detection of chromogranin A mRNA with traditional histological lymph node staging of small intestinal neuroendocrine neoplasia.
    Lawrence B; Kenney B; Svejda B; Schimmack S; Alaimo D; Barbieri A; Jedrych J; Kidd M; Modlin I
    BMC Res Notes; 2012 Jun; 5():318. PubMed ID: 22720672
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Usefulness of chromogranin A, neuron-specific enolase and 5-hydroxyindolacetic acid measurements in patients with malignant carcinoids.
    Manfé AZ; Norberto L; Marchesini M; Lumachi F
    In Vivo; 2011; 25(6):1027-9. PubMed ID: 22021701
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
    Lindholm DP; Oberg K
    Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors.
    Stokkel MP; Rietbergen DD; Korse CM; Taal BG
    Nucl Med Commun; 2011 Aug; 32(8):731-7. PubMed ID: 21633314
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.